Do Price Falls Make Banco Santander SA, Centrica PLC And GlaxoSmithKline plc Look Like Bargains?

Banco Santander SA (LON: BNC), Centrica PLC (LON: CNS) and GlaxoSmithKline plc (LON: GSK) are looking tempting.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

We usually hear much wailing when the FTSE 100 falls, and it’s down around 100 points today due to what’s happening in Greece. But those investing for the long term should rejoice and look for opportunities to pick up some bargain shares, and I’ve been checking out a few that could make for nice bargains now…

Banking

Banco Santander (LSE: BNC)(NYSE: SAN.US) shares have fallen 21% over the past 12 months, to 455p — and that comes after the bank has reversed its earnings decline, put in two years of strong growth, and is forecast to see EPS rise by 12% this year and 11% next. The dividend has been slashed, but that ended a crazy policy of paying very high dividends that were nowhere near covered by earnings, in the hope that people would take scrip instead of cash — we’re now looking at yields forecast of 2.9% and 3.3%.

The P/E would drop to 12.8 this year and 11.5% next, based on current expectations, which is a good bit below the FTSE average. But there is the fact that Santander is based in Spain, and there must be fears that Spain could go the way of Greece, so that’s possibly holding the price down.

Energy

A strong high-dividend utilities company can be a good one to have in your portfolio, and Centrica (LSE: CNA) fits the bill nicely. Its dividend is expected to drop a little this year, but should still yield around 4.4% — and the City is predicting a rise to 4.5% a year later.

But over the past year the share price has fallen 12% to 39p, and by 24% over two years. That’s partly justified by a fall to a lower lever of earnings on the back of plummeting oil prices and a competitive pricing squeeze, but the shares are still on a forward P/E of about 15 — and I think that’s good value for such a solid dividend payer.

Pills and potions

Finally I come to GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US), whose shares are down 13% in a year — 2015 started out strongly, but since a peak in April the price has fallen back down to 1,359p. Our big FTSE 100 pharmaceuticals companies have been struggling to get back to earnings growth in recent years, and AstraZeneca was looking like the turnaround star for a while. But 2015 is expected to see the end of the slump for Glaxo with a 16% fall in EPS, and then a return to growth with a 10% rise pencilled in for 2016.

Dividend yields of better than 6% should only just be covered, but if we do get the likely growth return, the firm should be able to maintain them. On a 2016 P/E of 15.5 is Glaxo a comeback bargain? It could well be.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »